Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment
| Status: | Archived |
|---|---|
| Conditions: | Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2009 |
| End Date: | January 2011 |
The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome
To determine whether the combination of ezetimibe and simvastatin improves biomarkers of
atherothrombosis compared to simvastatin alone in patients with the metabolic syndrome.
1. To assess the ex vivo effects of ezetimibe/simvastatin (E/S) (Vytorin 10/40mg) and
simvastatin (S) (Zocor 40mg) on platelet and inflammation biomarkers in patients with
documented metabolic syndrome.
2. To compare platelet-related effects including PAR-1 receptor inhibition of E/S with
those of the established anti-platelet agents including aspirin, clopidogrel,
intravenous and oral glycoprotein IIb/IIIa inhibitors.
3. To determine whether the addition of ezetimibe will yield extra protection beyond lipid
modulation in the reduction of inflammation and platelet activation.
We found this trial at
3
sites
University of Maryland, Baltimore Welcome to the University of Maryland, Baltimore (UMB) founded in 1807...
Click here to add this to my saved trials
Johns Hopkins Hosp From the 1889 opening of The Johns Hopkins Hospital, to the opening...
Click here to add this to my saved trials
Click here to add this to my saved trials